MA53500A - Composition d'agent thérapeutique et procédé d'utilisation, pour le traitement d'un trouble cognitif léger, de la dépression et de troubles psychologiques - Google Patents
Composition d'agent thérapeutique et procédé d'utilisation, pour le traitement d'un trouble cognitif léger, de la dépression et de troubles psychologiquesInfo
- Publication number
- MA53500A MA53500A MA053500A MA53500A MA53500A MA 53500 A MA53500 A MA 53500A MA 053500 A MA053500 A MA 053500A MA 53500 A MA53500 A MA 53500A MA 53500 A MA53500 A MA 53500A
- Authority
- MA
- Morocco
- Prior art keywords
- depression
- therapeutic agent
- agent composition
- mild cognitive
- cognitive disorder
- Prior art date
Links
- 208000010877 cognitive disease Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 208000020016 psychiatric disease Diseases 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671466P | 2018-05-15 | 2018-05-15 | |
| US201862671485P | 2018-05-15 | 2018-05-15 | |
| US201862674855P | 2018-05-22 | 2018-05-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53500A true MA53500A (fr) | 2021-08-18 |
Family
ID=68541027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053500A MA53500A (fr) | 2018-05-15 | 2019-05-15 | Composition d'agent thérapeutique et procédé d'utilisation, pour le traitement d'un trouble cognitif léger, de la dépression et de troubles psychologiques |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11090303B2 (enExample) |
| EP (1) | EP3843768A4 (enExample) |
| JP (2) | JP7699378B2 (enExample) |
| CN (1) | CN112423774A (enExample) |
| AU (1) | AU2019271189A1 (enExample) |
| BR (1) | BR112020023252A2 (enExample) |
| GB (1) | GB202015788D0 (enExample) |
| MA (1) | MA53500A (enExample) |
| WO (1) | WO2019222339A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA53500A (fr) | 2018-05-15 | 2021-08-18 | Lloyd Hung Loi Tran | Composition d'agent thérapeutique et procédé d'utilisation, pour le traitement d'un trouble cognitif léger, de la dépression et de troubles psychologiques |
| US20240398792A1 (en) * | 2018-05-15 | 2024-12-05 | Lloyd Hung Loi Tran | Therapeutic agent composition and method of use, for treating, relieving, or alleviating alzheimer's disease |
| CA3179317A1 (en) | 2020-04-20 | 2021-10-28 | Lloyd Hung Loi TRAN | Methods for the prophylaxis and treatment of covid and covid-19 |
| WO2022051631A1 (en) | 2020-09-03 | 2022-03-10 | University Of Notre Dame Du Lac | Therapy to stimulate hippocampal neural progenitors and adult neurogenesis |
| IL305132A (en) * | 2021-02-12 | 2023-10-01 | Neuren Pharmaceuticals Ltd | Preparations for the treatment of the Prader-Willi phenomenon |
| CN114582507A (zh) * | 2022-03-04 | 2022-06-03 | 青海省畜牧兽医科学院 | 基于地理探测器的泡型包虫病环境风险因子分析方法 |
| KR20260049797A (ko) * | 2023-07-12 | 2026-04-14 | 로이드 트란 | 경도 인지 장애 치료를 위한 병용 요법의 치료제 조성물 및 사용 방법 |
| WO2025088052A1 (en) * | 2023-10-26 | 2025-05-01 | Rousselot Bv | Cyclic analogue of glycine-proline for use in the prevention and/or treatment of medical implant-related fibrosis |
| WO2025160184A1 (en) * | 2024-01-23 | 2025-07-31 | Lloyd Tran | Methods for the prophylaxis and treatment of obesity and related conditions and disorders |
| WO2025179250A1 (en) * | 2024-02-25 | 2025-08-28 | Lloyd Tran | Methods for the prophylaxis and treatment of autism related disorders |
| WO2025198995A1 (en) * | 2024-03-18 | 2025-09-25 | Lloyd Tran | Methods for the prophylaxis and treatment of stroke related disorders |
| WO2026112551A1 (en) * | 2024-11-24 | 2026-05-28 | Lloyd Tran | Methods for the prophylaxis and treatment of substance use disorder (sud) including but not limited to alcohol use disorder (aud) |
| CN119770491B (zh) * | 2024-12-20 | 2025-10-17 | 北京大学 | 环甘氨酸-脯氨酸在制备治疗暴食症的药物中的应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2670563B2 (ja) | 1988-10-12 | 1997-10-29 | 富士通株式会社 | 半導体装置の製造方法 |
| JP2757960B2 (ja) | 1988-10-17 | 1998-05-25 | サントリー株式会社 | （２Ｒ，３Ｓ，４Ｓ）−α−（カルボキシシクロプロピル）グリシン |
| SE8803847A0 (sv) | 1988-10-27 | 1990-04-28 | Kabigen Ab | Neuromodulerande peptid |
| ES2101865T3 (es) | 1991-08-01 | 1997-07-16 | Genentech Inc | Igf-1 para mejorar el estado neural. |
| US5439930A (en) | 1992-04-14 | 1995-08-08 | Russian-American Institute For New Drug Development | Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects |
| CA2178711A1 (en) | 1993-12-23 | 1995-06-29 | Peter David Gluckman | Composition and methods to improve neural outcome |
| US5840736A (en) | 1996-11-13 | 1998-11-24 | Vertex Pharmaceuticals Incorporated | Methods and compositions for stimulating neurite growth |
| US5942422A (en) | 1996-11-14 | 1999-08-24 | The Trustees Of Columbia University In The City Of New York | Method for generating a directed, recombinant fusion nucleic acid |
| US6015786A (en) | 1997-02-25 | 2000-01-18 | Celtrix Pharmaceuticals, Inc. | Method for increasing sex steroid levels using IGF or IGF/IGFBP-3 |
| US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
| US6187906B1 (en) | 1997-08-11 | 2001-02-13 | Aukland Uniservices Limited | Methods to improve neural outcome |
| US6124361A (en) | 1997-12-31 | 2000-09-26 | Pfizer Inc | Bicyclo[3.1.0]hexanes and related compounds |
| IL138342A0 (en) | 1998-03-17 | 2001-10-31 | Pfizer Prod Inc | Bicyclo[2.2.1] heptanes and related compounds |
| US6258582B1 (en) | 1998-09-30 | 2001-07-10 | Millennium Pharmaceuticals, Inc. | CSAPTP nucleic acid molecules and uses therefor |
| US6303576B1 (en) | 1999-04-21 | 2001-10-16 | Adherex Technologies Inc. | Compounds and methods for modulating β-catenin mediated gene expression |
| KR20020079731A (ko) | 1999-11-05 | 2002-10-19 | 액소닉스, 인코포레이티드. | 아밀로이드, 아밀로이드-유사 침착물, 또는 β-쉬이트가풍부한 그의 병리학적 전구체로의 비정상적 단백질 폴딩과관련된 질환의 치료에 있어서 생체내에서 사용하기에적합한 펩티드 동족체 및 유사체 |
| US6689904B2 (en) | 2001-06-29 | 2004-02-10 | Wyeth | Bridged tricyclic analogs of 2-(carboxycyclopropyl)glycine |
| AU2002340465A1 (en) | 2001-11-09 | 2003-05-19 | Neuronz Biosciences, Inc. | Cyclo(prolyl-glycine) and methods of use to treat neural disorders |
| US20100247483A1 (en) * | 2001-11-13 | 2010-09-30 | Tran Loi H | Therapeutic agent composition and method of use |
| CA2466701C (en) * | 2001-11-13 | 2013-11-12 | Loi Tran | Neuroprotective use of cyclic prolyl glycine |
| US7232798B2 (en) | 2001-11-13 | 2007-06-19 | Tran Loi H | Neuroprotection and neuroegenisis by administering cyclic prolyl glycine |
| US20050209142A1 (en) | 2002-11-20 | 2005-09-22 | Goran Bertilsson | Compounds and methods for increasing neurogenesis |
| US6969702B2 (en) | 2002-11-20 | 2005-11-29 | Neuronova Ab | Compounds and methods for increasing neurogenesis |
| EP1664050B1 (en) * | 2003-09-03 | 2015-12-09 | Neuren Pharmaceuticals Limited | Neuroprotective bicyclic compounds and pharmaceutical compositions containing them |
| US8791117B2 (en) * | 2003-09-03 | 2014-07-29 | Neuren Pharmaceuticals Limited | Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals |
| EP1870097A1 (en) * | 2006-06-15 | 2007-12-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders |
| US8263547B2 (en) | 2008-05-28 | 2012-09-11 | Massachusetts Institute Of Technology | DISC-1 pathway activators in the control of neurogenesis |
| US20110288011A1 (en) | 2008-12-05 | 2011-11-24 | Jean-Paul Castaigne | Peptide therapeutic conjugates and uses thereof |
| SI3024463T1 (sl) * | 2013-07-25 | 2020-08-31 | Neuren Pharmaceuticals Limited | Nevroprotektivne biciklične spojine in postopki za njihovo uporabo pri zdravljenju motenj avtističnega spektra in nevrorazvojnih motenj |
| EP3551354B1 (en) * | 2018-02-19 | 2021-09-08 | The Material Works, Ltd. | Width and speed control for sheet metal descaler and methods of using same |
| MA53500A (fr) | 2018-05-15 | 2021-08-18 | Lloyd Hung Loi Tran | Composition d'agent thérapeutique et procédé d'utilisation, pour le traitement d'un trouble cognitif léger, de la dépression et de troubles psychologiques |
-
2019
- 2019-05-15 MA MA053500A patent/MA53500A/fr unknown
- 2019-05-15 EP EP19804060.2A patent/EP3843768A4/en active Pending
- 2019-05-15 BR BR112020023252-1A patent/BR112020023252A2/pt not_active IP Right Cessation
- 2019-05-15 GB GBGB2015788.9A patent/GB202015788D0/en not_active Ceased
- 2019-05-15 CN CN201980047677.1A patent/CN112423774A/zh active Pending
- 2019-05-15 JP JP2021514303A patent/JP7699378B2/ja active Active
- 2019-05-15 US US16/412,759 patent/US11090303B2/en active Active
- 2019-05-15 AU AU2019271189A patent/AU2019271189A1/en not_active Abandoned
- 2019-05-15 WO PCT/US2019/032403 patent/WO2019222339A1/en not_active Ceased
-
2021
- 2021-06-26 US US17/359,515 patent/US20220000866A1/en not_active Abandoned
-
2023
- 2023-05-11 US US18/315,910 patent/US12070458B2/en active Active
-
2025
- 2025-01-31 JP JP2025014460A patent/JP2025084741A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3843768A1 (en) | 2021-07-07 |
| WO2019222339A1 (en) | 2019-11-21 |
| JP2025084741A (ja) | 2025-06-03 |
| US20230381175A1 (en) | 2023-11-30 |
| US11090303B2 (en) | 2021-08-17 |
| JP7699378B2 (ja) | 2025-06-27 |
| US20200054629A1 (en) | 2020-02-20 |
| CN112423774A (zh) | 2021-02-26 |
| BR112020023252A2 (pt) | 2021-02-23 |
| GB202015788D0 (en) | 2020-11-18 |
| EP3843768A4 (en) | 2022-11-23 |
| AU2019271189A1 (en) | 2021-01-07 |
| US20220000866A1 (en) | 2022-01-06 |
| JP2021524864A (ja) | 2021-09-16 |
| US12070458B2 (en) | 2024-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3843768A4 (en) | THERAPEUTIC COMPOSITION AND METHODS OF USE IN THE TREATMENT OF MILD COGNITIVE IMPAIRMENT, DEPRESSION AND MENTAL DISORDERS | |
| MA51568A (fr) | Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central | |
| EP3955937A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES | |
| EP3927706A4 (en) | IMIDAZOPYRIDINYL COMPOUNDS AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | |
| EP3448389A4 (en) | CHINAZOLINE AND INDOIND DERIVATIVES FOR THE TREATMENT OF MEDICAL DISORDER | |
| MA47608A (fr) | Anticorps humanisé pour le traitement ou la prévention de troubles cognitifs, son procédé de production et agent pour le traitement ou la prévention de troubles cognitifs l'utilisant | |
| EP3484577A4 (en) | METHODS AND SYSTEMS FOR TREATING PELVIC DISEASES AND PAIN CONDITIONS | |
| EP3841086A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MEDICAL DISORDERS RELATED TO COMPLEMENT FACTOR D | |
| EP4364160A4 (en) | Digital device and application for the treatment of mild cognitive impairment and dementia | |
| EP4164720A4 (en) | System and method for treating post traumatic stress disorder (ptsd) and phobias | |
| EP3790425A4 (en) | APPLICATOR AND SYSTEM FOR PHARMACEUTICAL PREPARATION AND METHODS OF USE | |
| EP4096661A4 (en) | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISEASES | |
| EP3856168A4 (en) | COMPOSITION AND USE FOR THE TREATMENT OF PARKINSON'S DISEASE AND RELATED DISEASES | |
| MA53622A (fr) | Dispositif d'aide à la marche et procédé de traitement de troubles de la marche | |
| EP3801489A4 (en) | ACYLATED DRUGS AND METHODS OF USE FOR THE TREATMENT OF AUTOIMMUNE DISEASES | |
| EP3955926A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES | |
| EP3976182A4 (en) | MODULATION OF THE EFFECTS OF GAMMA CYTOKINE SIGNALING FOR THE TREATMENT OF ALOPECIA AND ALOPECIA-ASSOCIATED DISORDERS | |
| EP4058037A4 (en) | FIBROBLAST-BASED THERAPY TO TREAT AND PREVENT STROKE | |
| EP3831821A4 (en) | COMPOUND FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM AND ITS USE | |
| EP3883552A4 (en) | CYANOARYL ANILINE COMPOUNDS FOR THE TREATMENT OF SKIN DISEASES | |
| EP3931178A4 (en) | LINKS TO PREVENTION AND TREATMENT OF POSTOPERATIVE COGNITIVE DYSFUNCTION | |
| MA55895A (fr) | Compositions d'oxymétazoline et procédés de traitement de troubles oculaires | |
| EP4232075A4 (en) | Compounds,compositions and methods of use to treat spinal fusions | |
| MA54275A (fr) | Procédé de fabrication de formes pharmaceutiques contenant des inhibiteurs des canaux task-1 et task-3 et leur utilisation pour le traitement de troubles respiratoires | |
| EP4143218A4 (en) | LINKS TO THE PREVENTION AND TREATMENT OF POST-INTENSIVE CARE COGNITIVE DYSFUNCTION AND COGNITIVE DYSFUNCTION DUE TO RESPIRATORY DISTRESS |